OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Trading 03-28 12:20:32 EDT

1.38

-0.05

-3.50%

High1.43	Low1.35	Vol37.64K
Open1.40	D1 Closing1.43	Amplitude5.59%
Mkt Cap46.83M	Tradable Cap33.12M	Total Shares33.94M
T/O52.27K	T/O Rate0.16%	Tradable Shares24.00M
P/B-6.48	ROE-2968.51%	EPS-0.32
52wk High1.74	52wk Low0.8075	P/E-4.30
Dividend0.00	Div.Yield0.00	ROA-291.87%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.38,"timestamp":1743178314120,"preClose":1.43,"halted":0,"volume":37642,"delay":0,"floatShares":24001647,"shares":33936582,"eps":-0.321215,"marketStatus":"Trading","change":-0.05,"latestTime":"03-28 12:20:30 EDT","open":1.4,"high":1.43,"low":1.3501,"amount":52267.723816,"amplitude":0.055874,"askPrice":1.38,"askSize":200,"bidPrice":1.35,"bidSize":301,"shortable":3,"etf":0,"ttmEps":-0.321215,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.35,"preClose":1.43,"latestTime":"09:27 EDT","volume":40,"amount":54.997996,"timestamp":1743168463855},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.43,"latestTime":"19:50 EDT","volume":841,"amount":1171.43,"timestamp":1743119435729},"volumeRatio":0.823362},"requestUrl":"/m/hq/s/OKYO","defaultTab":"news","newsList":[{"id":"2518306229","title":"OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2518306229","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518306229?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:57","pubTimestamp":1741611468,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On March 10, 2025, OKYO Pharma Limited announced the filing of an ap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-seeks-fda-fast-track-for-urcosimod-in-treating-neuropathic-corneal-pain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-seeks-fda-fast-track-for-urcosimod-in-treating-neuropathic-corneal-pain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFXG0V08.USD","BK4104","BK4588","BK4139","BK4585","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","OKYO","BK4567","FAST"],"gpt_icon":0},{"id":"2518225740","title":"OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225740","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225740?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:30","pubTimestamp":1741609800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, March  10, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039726/0/en/OKYO-Pharma-Files-for-Fast-Track-Designation-with-FDA-for-Urcosimod-to-Treat-Neuropathic-Corneal-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNQmain","QID",".IXIC","SQQQ","USJW.SI","QLD","USAW.SI","PSQ","NQmain","NVIW.SI","TQQQ","FAST","TSYW.SI","OKYO"],"gpt_icon":1},{"id":"2512159020","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159020","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159020?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:18","pubTimestamp":1739881080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:18 ET (12:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2512949159","title":"H.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512949159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512949159?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:08","pubTimestamp":1739880527,"startTime":"0","endTime":"0","summary":"In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on OKYO Pharma Limited Sponsored ADR (OKYO – Research Report), wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-okyo-pharma-limited-sponsored-adr-okyo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-okyo-pharma-limited-sponsored-adr-okyo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO"],"gpt_icon":0},{"id":"2511615867","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2511615867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511615867?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 02:11","pubTimestamp":1739556660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 14, 2025 13:11 ET (18:11 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2511613425","title":"Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511613425?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 01:25","pubTimestamp":1739553914,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-recommendation-for-okyo-pharma-driven-by-promising-urcosimod-efficacy-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-recommendation-for-okyo-pharma-driven-by-promising-urcosimod-efficacy-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2510375510","title":"OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2510375510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510375510?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 20:28","pubTimestamp":1739363294,"startTime":"0","endTime":"0","summary":"The latest update is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On February 12, 2025, OKYO Pharma announced that its lead asset, OK-10...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-lead-asset-ok-101-receives-usan-as-urcosimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-lead-asset-ok-101-receives-usan-as-urcosimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2510837580","title":"Okyo Pharma announces OK-101 officially assigned USAN, urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2510837580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510837580?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 20:27","pubTimestamp":1739363277,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary Jaco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2510378223","title":"OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2510378223","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510378223?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 20:00","pubTimestamp":1739361600,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb. 12, 2025  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain , a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease , a multi-billion-dollar market, is pleased to announce that its lead asset, OK-101, has been officially assigned the United States Adopted Name  \"urcosimod\".The USAN designation reflects Okyo Pharma’s commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways, critical to addressing ocular conditions such as neuropathic corneal pain  and dry eye disease .Okyo Pharma’s innovative lipid-conjugated small molecule platform enables urcosimod to target and modulate ocular G-protein coupled receptors , reducing inflammation and pain at the source. The drug’s design, combining ant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-announces-ok-101-120000071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MNQmain","QID",".IXIC","SQQQ","USJW.SI","QLD","USAW.SI","NQmain","NVIW.SI","TQQQ","PSQ","TSYW.SI","OKYO"],"gpt_icon":1},{"id":"2510604658","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510604658","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510604658?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 01:02","pubTimestamp":1739206920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2025 12:02 ET (17:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2510286997","title":"Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2510286997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510286997?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 23:15","pubTimestamp":1739200516,"startTime":"0","endTime":"0","summary":"In a report released on February 7, Yi Chen from H.C. Wainwright reiterated a Buy rating on OKYO Pharma Limited Sponsored ADR (OKYO – Research Repo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/yi-chens-buy-recommendation-on-okyo-pharma-promising-potential-of-ok-101-for-neuropathic-corneal-pain-amid-financial-and-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/yi-chens-buy-recommendation-on-okyo-pharma-promising-potential-of-ok-101-for-neuropathic-corneal-pain-amid-financial-and-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2507595488","title":"Okyo Pharma CEO purchases 10,000 shares of company","url":"https://stock-news.laohu8.com/highlight/detail?id=2507595488","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507595488?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 20:06","pubTimestamp":1738325189,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) has been notified that the CEO Gary Jacob has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of $1.04 pe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-ceo-purchases-10000-shares-of-company?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-ceo-purchases-10000-shares-of-company?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["USAW.SI","NVIW.SI","TQQQ","NQmain","PSQ","OKYO",".IXIC","QID","TSYW.SI","BK4139","USJW.SI","MNQmain","QLD","SQQQ"],"gpt_icon":0},{"id":"2507510539","title":"OKYO Pharma Announces Chairman and CEO Acquire Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2507510539","media":"GlobeNewswire","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507510539?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 20:00","pubTimestamp":1738324800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Jan.  31, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/31/3018711/0/en/OKYO-Pharma-Announces-Chairman-and-CEO-Acquire-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNQmain","QID",".IXIC","SQQQ","USJW.SI","QLD","USAW.SI","NQmain","NVIW.SI","TQQQ","PSQ","TSYW.SI","OKYO"],"gpt_icon":1},{"id":"2507473624","title":"Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2507473624","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507473624?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 22:45","pubTimestamp":1738248300,"startTime":"0","endTime":"0","summary":"Tracing its roots to 2018, OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain  and inflammatory dry eye disease . Its lead drug candidate OK-101 successfully completed a 240-patient Phase 2 trial in DED patients and is also currently being evaluated in a 48-patient, randomized, placebo-controlled Phase 2 trial in NCP patients that seeks to demonstrate OK-101's ability to reduce neuropathic corneal pain. If an award of orphan drug designation to NCP, should happen, it could lead to a multi-billion dollar market opportunity for OKYO.In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming milestones and how these milestones and the flurry of M&A in the segment can favorably impact OKYO's near term and long term valuations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/goldman-small-cap-research-publishes-144500276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","IE0004086264.USD","LU2237443382.USD","BK4552","LU1791807156.HKD","LU2237443978.SGD","LU0106831901.USD","LU2237443549.SGD","BK4585","LU2237438978.USD","BK4504","LU1668664300.SGD","LU2237443465.HKD","IE0004091025.USD","IE00BFXG1179.USD","BK4139","IE00B19Z3581.USD","IE0034235188.USD","LU2237443622.USD","IE0002270589.USD","IE00B19Z3B42.SGD","OKYO","BK4533","LU2237443895.HKD","BK4588","BK4550","IE00BSNM7G36.USD","BK4127"],"gpt_icon":0},{"id":"2507669460","title":"OKYO Pharma Advances Clinical Trials with Encouraging Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669460","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507669460?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 05:56","pubTimestamp":1738187803,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On January 29, 2025, OKYO Pharma Limited provided a clinical update ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-clinical-trials-with-encouraging-interim-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-clinical-trials-with-encouraging-interim-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2507382136","title":"Okyo Pharma to complete enrollment of NCP trial by end of Q2, OK-101 update","url":"https://stock-news.laohu8.com/highlight/detail?id=2507382136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507382136?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 21:05","pubTimestamp":1738155908,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announces a clinical update and its interim results for the six months ended 30 September 2024. Neuropathic Corneal Pain, NCP: T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-to-complete-enrollment-of-ncp-trial-by-end-of-q2-ok-101-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-to-complete-enrollment-of-ncp-trial-by-end-of-q2-ok-101-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2507638128","title":"OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638128","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638128?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Jan. 29, 2025  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain , a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease , a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024.The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be a major binary event for the Company.During the past six months of 2024 the OKYO Pharma’s primary focus has been centered on preparations for and the initiation of the first clinical trial of a drug to treat NCP, with the announcement on 23 October, 2024 of the opening of a Phase 2a trial of OK-101 to treat NCP. The Phase 2a study is designed as a double-masked, randomized, 12-week p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-complete-enrollment-neuropathic-130000632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2505519092","title":"Okyo Pharma receives $1.4M in non-dilutive financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2505519092","media":"TipRanks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505519092?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 20:11","pubTimestamp":1737634283,"startTime":"0","endTime":"0","summary":"OKYO Pharma  has received $1.4M in non-dilutive funding. The company said, “This significant financial funding strengthens the Company’s ability to advance its innovative pipeline without diluting shareholder value. The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.”Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.OKYO Pharma to Highlight Innovations at BTIG Conference","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/okyo-pharma-receives-1-4m-121123227.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-receives-1-4m-121123227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2505745270","title":"Press Release: OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2505745270","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505745270?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 20:00","pubTimestamp":1737547200,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Jan. 22, 2025  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain , a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease , a multi-billion-dollar market, is pleased to announce that it has received $1.4 million in non-dilutive funding. This significant financial funding strengthens the Company's ability to advance its innovative pipeline without diluting shareholder value.The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO's lead program, OK-101 focused on treating NCP, a major unmet medical need.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","BK4139","QID","SQQQ","TQQQ","OKYO","NQmain","USAW.SI","NVIW.SI","MNQmain","TSYW.SI","USJW.SI","PSQ",".IXIC"],"gpt_icon":1},{"id":"2486740860","title":"OKYO Pharma to Highlight Innovations at BTIG Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486740860","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486740860?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 20:29","pubTimestamp":1732624164,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited is set to participate in the 4th Annual BTIG Ophthalmology Con...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-highlight-innovations-at-btig-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-highlight-innovations-at-btig-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":0.1349},{"period":"1month","weight":0.2655},{"period":"3month","weight":0.2328},{"period":"6month","weight":0.4089},{"period":"1year","weight":-0.0467},{"period":"ytd","weight":0.2436}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction